Cyclacel Pharmaceuticals Earnings Estimate

CYCC
 Stock
  

USD 0.77  0.10  11.49%   

Many public companies, such as Cyclacel Pharmaceuticals, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Cyclacel Pharmaceuticals' earnings estimates, investors can diagnose different trends across Cyclacel Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes.
Cyclacel Pharmaceuticals is projected to generate -2.27 in earnings per share on the 31st of December 2021. Cyclacel Pharmaceuticals earnings estimates module stress-tests analyst consensus about projected Cyclacel Pharmaceuticals EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Continue to Trending Equities.
  

Cyclacel Pharmaceuticals Earnings Estimation Breakdown

Calculation of earning per share of Cyclacel Pharmaceuticals is based on official Zacks consensus of 2 analysts regarding Cyclacel Pharmaceuticals future annual earnings. Given the historical accuracy of 70.6%, the future earnings per share of Cyclacel Pharmaceuticals is estimated to be -2.27 with the lowest and highest values of -2.33 and -2.24, respectively. Please note that this consensus of annual earnings estimates for Cyclacel Pharmaceuticals is an estimate of EPS before non-recurring items and including employee stock options expenses
  Current EPS -2.05
-2.33
Lowest
Expected EPS -2.27
-2.24
Highest

Cyclacel Pharmaceuticals Earnings Projection Consensus

Suppose the current estimates of Cyclacel Pharmaceuticals' value are higher than the current market price of the Cyclacel Pharmaceuticals stock. In this case, investors may conclude that Cyclacel Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Cyclacel Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021

2

70.6%

-2.047

-2.27

Cyclacel Pharmaceuticals Earnings per Share Projection vs Actual

Actual Earning per Share of Cyclacel Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Cyclacel Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Cyclacel Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Cyclacel Pharmaceuticals Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Cyclacel Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Cyclacel Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.

Cyclacel Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Cyclacel Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-11-09
2022-09-30-0.56-0.420.1425 
2022-08-10
2022-06-30-0.62-0.460.1625 
2022-05-11
2022-03-31-0.68-0.420.2638 
2022-03-28
2021-12-31-0.65-0.540.1116 
2021-11-10
2021-09-30-0.65-0.540.1116 
2021-08-11
2021-06-30-0.5-0.56-0.0612 
2021-05-12
2021-03-31-0.49-0.5-0.01
2021-02-25
2020-12-31-0.51-1.34-0.83162 
2020-11-11
2020-09-30-0.55-0.470.0814 
2020-08-12
2020-06-30-0.47-0.58-0.1123 
2020-05-12
2020-03-31-2.9-1.481.4248 
2020-02-26
2019-12-31-2.7-2.8-0.1
2019-11-13
2019-09-30-3.13-2.20.9329 
2019-08-13
2019-06-30-3.13-2.20.9329 
2019-05-14
2019-03-31-4.1-2.81.331 
2019-03-27
2018-12-31-3.47-3.40.07
2018-11-12
2018-09-30-3.4-3.6-0.2
2018-08-09
2018-06-30-2.4-3.2-0.833 
2018-05-14
2018-03-31-2.6-2.40.2
2018-03-28
2017-12-31-0.73-3.2-2.47338 
2017-11-02
2017-09-30None-18.2None
2017-08-09
2017-06-30None-0.5None
2017-05-11
2017-03-31None-0.38None
2017-03-28
2016-12-31-0.73-0.690.04
2016-11-14
2016-09-30-0.94-0.860.08
2016-08-10
2016-06-30-0.94-20.0987-19.15872038 
2016-05-11
2016-03-31None-20.8484None
2016-03-24
2015-12-31-0.96-1.2-0.2425 
2015-11-12
2015-09-30-1.08-0.960.1211 
2015-08-11
2015-06-30None-23.7079None
2015-05-12
2015-03-31-3-2.280.7224 
2015-03-24
2014-12-31-3.12-2.520.619 
2014-11-11
2014-09-30-3.12-2.640.4815 
2014-08-12
2014-06-30-72-52.819.226 
2014-05-13
2014-03-31-63.2-603.2
2014-03-25
2013-12-31-80-45.634.443 
2013-11-12
2013-09-30-76.8-76.80
2013-08-14
2013-06-30-8424108128 
2013-05-14
2013-03-31None-283.6224None
2013-03-28
2012-12-31None-143.1582None
2012-11-13
2012-09-30None-58.9944None
2012-08-14
2012-06-30-134.4-100.833.625 
2012-05-14
2012-03-31-134.4-100.833.625 
2012-03-29
2011-12-31-134.4-117.616.812 
2011-11-14
2011-09-30-140-117.622.416 
2011-08-11
2011-06-30-179.2-134.444.825 
2011-05-12
2011-03-31-142.8-168-25.217 
2011-03-23
2010-12-31-168-117.650.430 
2010-11-11
2010-09-30-252-184.867.226 
2010-08-05
2010-06-30-277.2-302.4-25.2
2010-05-13
2010-03-31-252-302.4-50.420 
2010-03-23
2009-12-31-310.8-302.48.4
2009-11-03
2009-09-30-369.6-218.4151.240 
2009-08-06
2009-06-30-428.4-571.2-142.833 
2009-05-14
2009-03-31-495.6-42075.615 
2009-03-31
2008-12-31-487.2-655.2-16834 
2008-11-06
2008-09-30-715.68-1444.8-729.12101 
2008-08-07
2008-06-30-672-705.6-33.6
2008-05-09
2008-03-31-576.8-520.856
2008-03-11
2007-12-31-756-940.8-184.824 
2007-11-07
2007-09-30-613.2-352.8260.442 
2007-08-09
2007-06-30-600.6-302.4298.249 
2007-05-10
2007-03-31-694.4-453.6240.834 
2007-03-15
2006-12-31-655.2-604.850.4
2006-11-13
2006-09-30-730.8-571.2159.621 
2006-08-14
2006-06-30-697.2-806.4-109.215 
2006-05-16
2006-03-31-940.8-3040.8-2100223 
2006-03-22
2005-12-31-3192-3024168
2005-11-14
2005-09-30-3864-10752-6888178 
2005-08-15
2005-06-30-5544-5040504
2005-05-16
2005-03-31-6468-6216252
2005-03-31
2004-12-31-8064-8400-336
2004-11-11
2004-09-30-7014-7728-71410 
2004-08-12
2004-06-30-6384-6888-504
2004-05-13
2004-03-31-5460-27048-21588395 

About Cyclacel Pharmaceuticals Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Cyclacel Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Cyclacel Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Cyclacel Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey. Cyclacel Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cyclacel Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cyclacel Pharmaceuticals' short interest history, or implied volatility extrapolated from Cyclacel Pharmaceuticals options trading.

Pair Trading with Cyclacel Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cyclacel Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cyclacel Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cyclacel Pharmaceuticals

+0.65BEAMBeam TherapeuticsInc Downward RallyPairCorr

Moving against Cyclacel Pharmaceuticals

-0.83MRKMerck Company Sell-off TrendPairCorr
-0.81CABACabaletta Bio TrendingPairCorr
-0.76JNJJohnson Johnson Sell-off TrendPairCorr
-0.75BMYBristol-Myers Squibb Sell-off TrendPairCorr
The ability to find closely correlated positions to Cyclacel Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cyclacel Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cyclacel Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cyclacel Pharmaceuticals to buy it.
The correlation of Cyclacel Pharmaceuticals is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cyclacel Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cyclacel Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cyclacel Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Cyclacel Pharmaceuticals information on this page should be used as a complementary analysis to other Cyclacel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Cyclacel Stock analysis

When running Cyclacel Pharmaceuticals price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Is Cyclacel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclacel Pharmaceuticals. If investors know Cyclacel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclacel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
10.9 M
Return On Assets
(0.42) 
Return On Equity
(0.60) 
The market value of Cyclacel Pharmaceuticals is measured differently than its book value, which is the value of Cyclacel that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclacel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cyclacel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclacel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cyclacel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclacel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Cyclacel Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclacel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.